Sular is a calcium channel blocking agent for the treatment of high blood pressure. The new Sular formulation utilizes SkyePharma’s patented Geomatrix technology, which is designed to provide a lower dose of Sular for each of its current doses.
The companies said that they expect to hear more from the FDA on November 2.